Hang Lung Group (HLU) 주식 개요투자 지주 회사인 항룽 그룹은 홍콩과 중국 본토에서 부동산 개발업체로 활동하고 있습니다. 자세히 보기HLU 펀더멘털 분석스노우플레이크 점수가치 평가2/6미래 성장0/6과거 실적1/6재무 건전성3/6배당6/6강점공정 가치 추정치보다 낮은 75.2% 에서 거래6.23% 의 높고 안정적인 배당금을 지급합니다.위험 분석재무 결과에 영향을 미치는 대규모 일회성 항목모든 위험 점검 보기HLU Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW480,107 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA480,107 investors already sharing narrativesYour Fair Value€Current Price€1.4751.5% 고평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-2b14b2016201920222025202620282031Revenue HK$11.5bEarnings HK$1.5bAdvancedSet Fair ValueView all narrativesHang Lung Group Limited 경쟁사AroundtownSymbol: XTRA:AT1Market cap: €2.1bGrand City PropertiesSymbol: XTRA:GYCMarket cap: €1.7bTAG ImmobilienSymbol: XTRA:TEGMarket cap: €2.4bDeutsche EuroShopSymbol: XTRA:DEQMarket cap: €1.4b가격 이력 및 성과Hang Lung Group 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가HK$1.4752주 최고가HK$1.8752주 최저가HK$1.35베타0.661개월 변동4.26%3개월 변동-15.03%1년 변동0%3년 변동4.26%5년 변동-27.94%IPO 이후 변동72.94%최근 뉴스 및 업데이트공고 • Jul 03Hang Lung Group Limited to Report First Half, 2026 Results on Jul 31, 2026Hang Lung Group Limited announced that they will report first half, 2026 results on Jul 31, 2026Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 5 independent directors on the board. The company's board is composed of: 5 independent directors. 6 non-independent directors. Independent Non-Executive Director May Tan was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공고 • Jan 30+ 1 more updateHang Lung Group Limited, Annual General Meeting, Apr 30, 2026Hang Lung Group Limited, Annual General Meeting, Apr 30, 2026.공고 • Jan 02Hang Lung Group Limited to Report Fiscal Year 2025 Results on Jan 30, 2026Hang Lung Group Limited announced that they will report fiscal year 2025 results on Jan 30, 2026공고 • Jul 03Hang Lung Group Limited to Report First Half, 2025 Results on Jul 30, 2025Hang Lung Group Limited announced that they will report first half, 2025 results on Jul 30, 2025공고 • Jan 24+ 1 more updateHang Lung Group Limited, Annual General Meeting, Apr 30, 2025Hang Lung Group Limited, Annual General Meeting, Apr 30, 2025.더 많은 업데이트 보기Recent updates공고 • Jul 03Hang Lung Group Limited to Report First Half, 2026 Results on Jul 31, 2026Hang Lung Group Limited announced that they will report first half, 2026 results on Jul 31, 2026Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 5 independent directors on the board. The company's board is composed of: 5 independent directors. 6 non-independent directors. Independent Non-Executive Director May Tan was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공고 • Jan 30+ 1 more updateHang Lung Group Limited, Annual General Meeting, Apr 30, 2026Hang Lung Group Limited, Annual General Meeting, Apr 30, 2026.공고 • Jan 02Hang Lung Group Limited to Report Fiscal Year 2025 Results on Jan 30, 2026Hang Lung Group Limited announced that they will report fiscal year 2025 results on Jan 30, 2026공고 • Jul 03Hang Lung Group Limited to Report First Half, 2025 Results on Jul 30, 2025Hang Lung Group Limited announced that they will report first half, 2025 results on Jul 30, 2025공고 • Jan 24+ 1 more updateHang Lung Group Limited, Annual General Meeting, Apr 30, 2025Hang Lung Group Limited, Annual General Meeting, Apr 30, 2025.공고 • Jan 03Hang Lung Group Limited to Report Fiscal Year 2024 Results on Jan 24, 2025Hang Lung Group Limited announced that they will report fiscal year 2024 results at 12:30 PM, China Standard Time on Jan 24, 2025Valuation Update With 7 Day Price Move • Oct 01Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €1.19, the stock trades at a trailing P/E ratio of 7.1x. Average trailing P/E is 13x in the Real Estate industry in Germany. Total loss to shareholders of 26% over the past three years.Reported Earnings • Sep 18First half 2024 earnings released: EPS: HK$0.65 (vs HK$1.24 in 1H 2023)First half 2024 results: EPS: HK$0.65 (down from HK$1.24 in 1H 2023). Revenue: HK$6.51b (up 16% from 1H 2023). Net income: HK$888.0m (down 47% from 1H 2023). Profit margin: 14% (down from 30% in 1H 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.Upcoming Dividend • Aug 07Upcoming dividend of HK$0.21 per shareEligible shareholders must have bought the stock before 14 August 2024. Payment date: 25 September 2024. Payout ratio is a comfortable 58% and this is well supported by cash flows. Trailing yield: 10%. Within top quartile of German dividend payers (4.9%). Higher than average of industry peers (2.9%).Reported Earnings • Aug 01First half 2024 earnings released: EPS: HK$0.65 (vs HK$1.24 in 1H 2023)First half 2024 results: EPS: HK$0.65 (down from HK$1.24 in 1H 2023). Revenue: HK$6.51b (up 16% from 1H 2023). Net income: HK$888.0m (down 47% from 1H 2023). Profit margin: 14% (down from 30% in 1H 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.New Risk • Jul 31New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 17% Last year net profit margin: 27% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Profit margins are more than 30% lower than last year (17% net profit margin).New Risk • Jul 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 18% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (6.7% average weekly change).공고 • Jul 04Hang Lung Group Limited to Report First Half, 2024 Results on Jul 30, 2024Hang Lung Group Limited announced that they will report first half, 2024 results on Jul 30, 2024공고 • Jun 21Hang Lung Group Limited Announces Audit Committee Changes, Effective July 1, 2024The board of Hang Lung Group Limited announced changes to the composition of the Audit Committee of the Company with effect from July 1, 2024. Professor Lap-Chee TSUI, an independent non-executive director of the Company, will cease to be a member of the Audit Committee; and Ms. May Siew Boi TAN, an independent non-executive director of the Company, will be appointed as a member of the Audit Committee. Professor TSUI will remain as an independent non-executive director of the Company.Reported Earnings • Mar 31Full year 2023 earnings released: EPS: HK$2.06 (vs HK$2.00 in FY 2022)Full year 2023 results: EPS: HK$2.06 (up from HK$2.00 in FY 2022). Revenue: HK$11.0b (flat on FY 2022). Net income: HK$2.81b (up 3.4% from FY 2022). Profit margin: 26% (in line with FY 2022). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.Recent Insider Transactions • Feb 09Executive Vice Chair of the Board recently bought €230k worth of stockOn the 2nd of February, Wenbwo Chan bought around 200k shares on-market at roughly €1.15 per share. This transaction amounted to 67% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Wenbwo has been a buyer over the last 12 months, purchasing a net total of €569k worth in shares.Declared Dividend • Feb 01Final dividend of HK$0.65 announcedShareholders will receive a dividend of HK$0.65. Ex-date: 8th May 2024 Payment date: 14th June 2024 Dividend yield will be 62%, which is higher than the industry average of 3.1%. Sustainability & Growth Dividend is well covered by both earnings (42% earnings payout ratio) and cash flows (25% cash payout ratio). The dividend has increased over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. The company's earnings per share (EPS) would need to decline by 54% to shift the payout ratio to a potentially unsustainable range, which is more than the 12% EPS decline seen over the last 5 years.공고 • Jan 31Hang Lung Properties Limited and Hang Lung Group Limited Announce Retirement of Mr. Ronnie Chichung Chan as the Chair, an Executive Director, and the Chair of Executive Committees, with Effect from April 26, 2024The Boards of Directors of Hang Lung Group Limited (HLG) and Hang Lung Properties Limited (HLP, together with HLG, referred to as the Group) jointly announced that Mr. Ronnie Chichung CHAN (Mr. Ronnie Chan) will retire from his positions as the Chair, an Executive Director, and the Chair of Executive Committees of the Group with effect from the conclusion of the annual general meeting of each of HLG and HLP to be held on April 26, 2024 (the "2024 AGM"). Mr. Ronnie Chan will not take up a Non-Executive Director role in the Boards after his retirement. Mr. Ronnie Chan joined the Group in 1972 and has led the Group as the Chair since 1991. Mr. Ronnie Chan's vision and leadership established a strong foundation for the Group's sustainable growth. The Boards would like to express their deep gratitude to Mr. Ronnie Chan for his tremendous contributions to the Group. In recognition of his tremendous contributions, the Boards will bestow upon Mr. Ronnie Chan the title of the "Honorary Chair" of the Group after his retirement.Reported Earnings • Jan 31Full year 2023 earnings released: EPS: HK$2.06 (vs HK$2.00 in FY 2022)Full year 2023 results: EPS: HK$2.06 (up from HK$2.00 in FY 2022). Revenue: HK$11.0b (flat on FY 2022). Net income: HK$2.81b (up 3.4% from FY 2022). Profit margin: 26% (up from 25% in FY 2022). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.공고 • Jan 30+ 1 more updateHang Lung Group Limited Appoints Ms. May Siew Boi Tan as an Independent Non-Executive Director, with Effect from March 20, 2024The Board of Directors of Hang Lung Group Limited announced that Ms. May Siew Boi TAN ("Ms. Tan") will be appointed as an Independent Non-Executive Director ("INED") of the Company with effect from March 20, 2024. Ms. Tan, aged 68, graduated from The University of Sheffield, and is a Fellow of The Institute of Chartered Accountants in England and Wales and a Fellow of The Hong Kong Institute of Certified Public Accountants. Ms. Tan is an INED, the Chair of the Audit & Risk Committee, and a Member of the Nomination Committee, the Finance & General Committee, the Sustainability Committee, and the Human Resources & Remuneration Committee, of CLP Holdings Limited. She is also an INED, a Member of the Audit Committee and the Corporate Governance and Nominating Committee, of Manulife Financial Corporation. She holds the positions as a Board Member of Anticimex New TopHolding AB; and a Director of MSIG Insurance (Hong Kong) Limited. Ms. Tan was an INED of JPMorgan China Growth & Income plc from August 2021 to January 2024; an INED of Link Asset Management Ltd. (as manager of Link Real Estate Investment Trust) from February 2013 to January 2022; and an INED of HSBC Insurance (Asia) Limited and HSBC Life (International) Limited from 2018 to 2021. She was an Executive Director and the Chief Executive Officer of Standard Chartered Bank (Hong Kong) Limited* from July 2014 to February 2017. Ms. Tan joined Standard Chartered Bank in 2009 as Global Head, Equity Corporate Finance. She was previously the Chief Executive Officer of Cazenove Asia Limited, and was a partner of Cazenove and Co. Cazenove Asia Limited (now known as Standard Chartered Securities (Hong Kong) Limited) became part of Standard Chartered Hong Kong in January 2009. Service from 2015 to 2020. In 2016, Ms. Tan was the Chairman of the Hong Kong Association of Banks, the Ex-officio Member of The Hong Kong Trade Development Council and a Member of the Currency Board Sub-Committee of the Exchange Fund Advisory Committee of Hong Kong Monetary Authority. She was a Member of the Listing Committee of The Stock Exchange of Hong Kong Limited from 2012 to 2015 and a Member of the Takeovers and Mergers Panel and the Takeovers Appeal Committee of the Securities and Futures Commission from 2001 to 2013. Ms. Tan was also a Council Member from 2008 to 2017 and the Vice Chairman from 2012 to 2017 of Oxfam Hong Kong.공고 • Jan 06Hang Lung Group Limited to Report Fiscal Year 2023 Results on Jan 30, 2024Hang Lung Group Limited announced that they will report fiscal year 2023 results on Jan 30, 2024Upcoming Dividend • Sep 05Upcoming dividend of HK$0.21 per share at 7.8% yieldEligible shareholders must have bought the stock before 12 September 2023. Payment date: 29 September 2023. Payout ratio is a comfortable 40% and this is well supported by cash flows. Trailing yield: 7.8%. Within top quartile of German dividend payers (4.8%). Higher than average of industry peers (3.6%).Reported Earnings • Aug 02First half 2023 earnings released: EPS: HK$1.24 (vs HK$1.06 in 1H 2022)First half 2023 results: EPS: HK$1.24 (up from HK$1.06 in 1H 2022). Revenue: HK$5.60b (down 2.2% from 1H 2022). Net income: HK$1.68b (up 17% from 1H 2022). Profit margin: 30% (up from 25% in 1H 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.공고 • Aug 01Hang Lung Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2023, Payable on 29 September 2023Hang Lung Group Limited announced Interim Dividend for the six months ended 30 June 2023 of HKD 0.21 per share. Ex-dividend date 12 September 2023. Record date 15 September 2023. Payment date 29 September 2023.공고 • Jul 04Hang Lung Group Limited to Report First Half, 2023 Results on Jul 31, 2023Hang Lung Group Limited announced that they will report first half, 2023 results on Jul 31, 2023Upcoming Dividend • Apr 26Upcoming dividend of HK$0.65 per share at 6.3% yieldEligible shareholders must have bought the stock before 03 May 2023. Payment date: 19 May 2023. Payout ratio is a comfortable 43% and this is well supported by cash flows. Trailing yield: 6.3%. Within top quartile of German dividend payers (4.6%). Higher than average of industry peers (3.9%).Reported Earnings • Apr 06Full year 2022 earnings released: EPS: HK$2.00 (vs HK$1.90 in FY 2021)Full year 2022 results: EPS: HK$2.00 (up from HK$1.90 in FY 2021). Revenue: HK$11.1b (up 1.7% from FY 2021). Net income: HK$2.72b (up 5.0% from FY 2021). Profit margin: 25% (in line with FY 2021). Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 9% per year.Buying Opportunity • Feb 16Now 20% undervaluedOver the last 90 days, the stock is up 13%. The fair value is estimated to be €2.14, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.7% over the last 3 years. Earnings per share has declined by 9.6%.Reported Earnings • Feb 02Full year 2022 earnings released: EPS: HK$2.00 (vs HK$1.90 in FY 2021)Full year 2022 results: EPS: HK$2.00 (up from HK$1.90 in FY 2021). Revenue: HK$10.9b (flat on FY 2021). Net income: HK$2.72b (up 5.0% from FY 2021). Profit margin: 25% (up from 24% in FY 2021). Over the last 3 years on average, earnings per share has fallen by 10% per year and the company’s share price has also fallen by 10% per year.공고 • Feb 01Hang Lung Group Limited Proposes Final Dividend for the Year Ended 31 December 2022, Payable on 19 May 2023Hang Lung Group Limited proposed Final Dividend of HKD 0.65 per share for the year ended 31 December 2022. Ex-dividend date is 03 May 2023. Record date is 05 May 2023. Payment date is 19 May 2023. Date of shareholders' approval is 28 April 2023.Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 5 experienced directors. 5 highly experienced directors. 4 independent directors (7 non-independent directors). Independent Non-Executive Director Pak Wai Liu was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Sep 18First half 2022 earnings released: EPS: HK$1.06 (vs HK$1.11 in 1H 2021)First half 2022 results: EPS: HK$1.06 (down from HK$1.11 in 1H 2021). Revenue: HK$5.72b (up 9.1% from 1H 2021). Net income: HK$1.44b (down 4.6% from 1H 2021). Profit margin: 25% (down from 29% in 1H 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.Upcoming Dividend • Sep 02Upcoming dividend of HK$0.21 per shareEligible shareholders must have bought the stock before 09 September 2022. Payment date: 29 September 2022. Payout ratio is a comfortable 46% and this is well supported by cash flows. Trailing yield: 6.4%. Within top quartile of German dividend payers (4.8%). Higher than average of industry peers (5.2%).Recent Insider Transactions • Aug 16CEO & Executive Director recently bought €83k worth of stockOn the 10th of August, Wai Pak Lo bought around 50k shares on-market at roughly €1.67 per share. This was the largest purchase by an insider in the last 3 months. Wai Pak has been a buyer over the last 12 months, purchasing a net total of €492k worth in shares.Reported Earnings • Jul 29First half 2022 earnings releasedFirst half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (down HK$1.51b from profit in 1H 2021). Profit margin: (down from 29% in 1H 2021). The decrease in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.공고 • Jul 29Hang Lung Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2022, Payable on 29 September 2022Hang Lung Group Limited announced Interim Dividend for the six months ended 30 June 2022. Dividend declared is HKD 0.21 per share. Ex-dividend date is 09 September 2022. Record date is 15 September 2022. Payment date is 29 September 2022.공고 • Jul 05Hang Lung Group Limited to Report First Half, 2022 Results on Jul 28, 2022Hang Lung Group Limited announced that they will report first half, 2022 results on Jul 28, 2022공고 • Apr 28Hang Lung Group Limited Approves Final DividendHang Lung Group Limited approved the final dividend of 65 Hong Kong cents per share in annual general meeting held on April 27, 2022.Board Change • Apr 27Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 7 experienced directors. 3 highly experienced directors. 4 independent directors (7 non-independent directors). Independent Non-Executive Director Pak Wai Liu was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Upcoming Dividend • Apr 22Upcoming dividend of HK$0.65 per shareEligible shareholders must have bought the stock before 29 April 2022. Payment date: 19 May 2022. Payout ratio is a comfortable 45% and this is well supported by cash flows. Trailing yield: 5.2%. Within top quartile of German dividend payers (3.8%). Higher than average of industry peers (3.7%).Reported Earnings • Jan 28Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: HK$1.90 (up from HK$1.13 loss in FY 2020). Revenue: HK$10.9b (up 18% from FY 2020). Net income: HK$2.59b (up HK$4.13b from FY 2020). Profit margin: 24% (up from net loss in FY 2020). The move to profitability was primarily driven by lower expenses. Revenue missed analyst estimates by 11%. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.공고 • Jan 28+ 1 more updateHang Lung Group Limited Proposes Final Dividend for the Year Ended December 31, 2021, Payable on May 19, 2022Hang Lung Group Limited proposed final dividend of HKD 0.65 per share for the year ended December 31, 2021. Ex-dividend date is April 29, 2022. Record date is May 04, 2022. Payment date is May 19, 2022.Reported Earnings • Sep 18First half 2021 earnings released: EPS HK$1.11 (vs HK$1.17 loss in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: HK$5.24b (up 22% from 1H 2020). Net income: HK$1.51b (up HK$3.10b from 1H 2020). Profit margin: 29% (up from net loss in 1H 2020). Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.Recent Insider Transactions • Sep 12CEO & Executive Director recently bought €307k worth of stockOn the 8th of September, Wai Pak Lo bought around 150k shares on-market at roughly €2.05 per share. This was the largest purchase by an insider in the last 3 months. This was Wai Pak's only on-market trade for the last 12 months.Upcoming Dividend • Sep 03Upcoming dividend of HK$0.21 per shareEligible shareholders must have bought the stock before 10 September 2021. Payment date: 29 September 2021. Trailing yield: 4.4%. Within top quartile of German dividend payers (3.1%). Higher than average of industry peers (2.9%).Recent Insider Transactions • Sep 02CFO & Executive Director recently bought €61k worth of stockOn the 26th of August, Hau Cheong Ho bought around 29k shares on-market at roughly €2.11 per share. This was the largest purchase by an insider in the last 3 months. Hau Cheong has been a buyer over the last 12 months, purchasing a net total of €107k worth in shares.Reported Earnings • Aug 02First half 2021 earnings released: EPS HK$1.11 (vs HK$1.17 loss in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: HK$5.24b (up 22% from 1H 2020). Net income: HK$1.51b (up HK$3.10b from 1H 2020). Profit margin: 29% (up from net loss in 1H 2020). Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.Executive Departure • May 07Director of General Counsel has left the companyOn the 1st of May, Ka Man Yan's tenure as Director of General Counsel ended after 3.8 years in the role. We don't have any record of a personal shareholding under Ka Man's name. Ka Man is the only executive to leave the company over the last 12 months.공고 • May 01Hang Lung Group Limited Declares Final Dividend for the Year 2020Hang Lung Group Limited declares a final dividend of 63 Hong Kong cents per share, at its AGM to be held on April 29, 2020.Upcoming Dividend • Apr 27Upcoming dividend of HK$0.63 per shareEligible shareholders must have bought the stock before 04 May 2021. Payment date: 20 May 2021. Trailing yield: 4.0%. Within top quartile of German dividend payers (3.2%). Higher than average of industry peers (3.1%).Reported Earnings • Mar 26Full year 2020 earnings released: HK$1.13 loss per share (vs HK$5.01 profit in FY 2019)The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2020 results: Revenue: HK$9.24b (down 4.0% from FY 2019). Net loss: HK$1.54b (down 123% from profit in FY 2019). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.Reported Earnings • Jan 29Full year 2020 earnings released: HK$1.13 loss per share (vs HK$5.01 profit in FY 2019)The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2020 results: Revenue: HK$9.53b (down 1.0% from FY 2019). Net loss: HK$1.54b (down 123% from profit in FY 2019). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.공고 • Jan 28Hang Lung Group Limited, Annual General Meeting, Apr 30, 2021Hang Lung Group Limited, Annual General Meeting, Apr 30, 2021.Is New 90 Day High Low • Jan 27New 90-day high: €2.26The company is up 19% from its price of €1.90 on 29 October 2020. The German market is up 21% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Real Estate industry, which is up 9.0% over the same period.공고 • Jan 07Hang Lung Group Limited to Report Fiscal Year 2020 Results on Jan 28, 2021Hang Lung Group Limited announced that they will report fiscal year 2020 results on Jan 28, 2021공고 • Nov 21Hang Lung Group Limited Enters into the Lease Agreement as Tenant with Hang Lung as the LandlordThe Board announced that Top Glorification, an indirect wholly-owned subsidiary of the Company, entered into the Lease Agreement as tenant with Hang Lung as the landlord in respect of the Premises on 20 November 2020, for a term of three years commencing on 1 November 2020 and expiring on 31 October 2023 (both days inclusive) for the operation of its restaurant "Duddell's". Pursuant to HKFRS 16, the entering into of the Agreement will require the Group to recognise the fixed portion of the lease payment for the Premises as the right-of-use assets with a cost of approximately HKD 19.0 million at initial recognition and a corresponding lease liability which represented the present value of the future lease payments. Thus, the entering into the Lease Agreement and the transactions contemplated thereunder will be regarded as deemed acquisition of asset by the Group. REASONS FOR AND BENEFITS OF ENTERING INTO THE LEASE AGREEMENT: The Group is principally engaged in operating restaurants and providing membership services for the Group's restaurants in Hong Kong. The Premises have been leased to Top Glorification since May 2013 to operate the Group 's restaurant "Duddell's". The existing lease agreement for the Premises will expire on 31 October 2020. The Lease Agreement allows "Duddell's" to operate in the same location at Premises after the expiry of the existing lease agreement on 31 October 2020, which will facilitate the long-term success of the restaurant. Based on the above, the Directors are of the view that the terms and conditions of the Lease Agreement are fair and reasonable and in the interests of the Company and its shareholders as a whole.Is New 90 Day High Low • Oct 31New 90-day low: €1.88The company is down 7.0% from its price of €2.02 on 31 July 2020. The German market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Real Estate industry, which is down 2.0% over the same period.Is New 90 Day High Low • Sep 29New 90-day low: €1.94The company is down 6.0% from its price of €2.06 on 01 July 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Real Estate industry, which is up 4.0% over the same period.주주 수익률HLUDE Real EstateDE 시장7D0%-0.6%0.1%1Y0%-19.7%-0.5%전체 주주 수익률 보기수익률 대 산업: HLU은 지난 1년 동안 -19.7%의 수익을 기록한 German Real Estate 산업보다 더 좋은 성과를 냈습니다.수익률 대 시장: HLU은 지난 1년 동안 -0.5%의 수익을 기록한 German 시장과 동일한 성과를 보였습니다.주가 변동성Is HLU's price volatile compared to industry and market?HLU volatilityHLU Average Weekly Movement2.9%Real Estate Industry Average Movement4.9%Market Average Movement5.3%10% most volatile stocks in DE Market12.7%10% least volatile stocks in DE Market2.7%안정적인 주가: HLU는 지난 3개월 동안 German 시장에 비해 주가 변동성이 크지 않았습니다.시간에 따른 변동성: HLU의 주간 변동성(3%)은 지난 1년 동안 안정적이었습니다.회사 소개설립직원 수CEO웹사이트19604,595Weber Lowww.hanglung.com투자 지주 회사인 항룽 그룹은 홍콩과 중국 본토에서 부동산 개발업체로 운영되고 있습니다. 부동산 임대, 부동산 판매, 호텔 부문을 통해 사업을 운영하고 있습니다. 이 회사는 소매, 사무실, 주거 및 서비스 아파트와 같은 판매 및 임대용 부동산을 개발합니다.더 보기Hang Lung Group Limited 기초 지표 요약Hang Lung Group의 순이익과 매출은 시가총액과 어떻게 비교됩니까?HLU 기초 통계시가총액€2.11b순이익 (TTM)€153.56m매출 (TTM)€1.17b13.7x주가수익비율(P/E)1.8x주가매출비율(P/S)HLU는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표HLU 손익계산서 (TTM)매출HK$10.46b매출원가HK$3.58b총이익HK$6.88b기타 비용HK$5.51b순이익HK$1.37b최근 보고된 실적Dec 31, 2025다음 실적 발표일Jul 31, 2026주당순이익(EPS)1.01총이익률65.80%순이익률13.10%부채/자본 비율35.3%HLU의 장기 실적은 어땠습니까?과거 실적 및 비교 보기배당6.2%현재 배당 수익률85%배당 성향View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/23 00:45종가2026/07/23 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Hang Lung Group Limited는 5명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Andrew LawrenceBarclaysAnthony WuGoldman SachsVenant ChiangJefferies LLC2명의 분석가 더 보기
공고 • Jul 03Hang Lung Group Limited to Report First Half, 2026 Results on Jul 31, 2026Hang Lung Group Limited announced that they will report first half, 2026 results on Jul 31, 2026
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 5 independent directors on the board. The company's board is composed of: 5 independent directors. 6 non-independent directors. Independent Non-Executive Director May Tan was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공고 • Jan 30+ 1 more updateHang Lung Group Limited, Annual General Meeting, Apr 30, 2026Hang Lung Group Limited, Annual General Meeting, Apr 30, 2026.
공고 • Jan 02Hang Lung Group Limited to Report Fiscal Year 2025 Results on Jan 30, 2026Hang Lung Group Limited announced that they will report fiscal year 2025 results on Jan 30, 2026
공고 • Jul 03Hang Lung Group Limited to Report First Half, 2025 Results on Jul 30, 2025Hang Lung Group Limited announced that they will report first half, 2025 results on Jul 30, 2025
공고 • Jan 24+ 1 more updateHang Lung Group Limited, Annual General Meeting, Apr 30, 2025Hang Lung Group Limited, Annual General Meeting, Apr 30, 2025.
공고 • Jul 03Hang Lung Group Limited to Report First Half, 2026 Results on Jul 31, 2026Hang Lung Group Limited announced that they will report first half, 2026 results on Jul 31, 2026
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 5 independent directors on the board. The company's board is composed of: 5 independent directors. 6 non-independent directors. Independent Non-Executive Director May Tan was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공고 • Jan 30+ 1 more updateHang Lung Group Limited, Annual General Meeting, Apr 30, 2026Hang Lung Group Limited, Annual General Meeting, Apr 30, 2026.
공고 • Jan 02Hang Lung Group Limited to Report Fiscal Year 2025 Results on Jan 30, 2026Hang Lung Group Limited announced that they will report fiscal year 2025 results on Jan 30, 2026
공고 • Jul 03Hang Lung Group Limited to Report First Half, 2025 Results on Jul 30, 2025Hang Lung Group Limited announced that they will report first half, 2025 results on Jul 30, 2025
공고 • Jan 24+ 1 more updateHang Lung Group Limited, Annual General Meeting, Apr 30, 2025Hang Lung Group Limited, Annual General Meeting, Apr 30, 2025.
공고 • Jan 03Hang Lung Group Limited to Report Fiscal Year 2024 Results on Jan 24, 2025Hang Lung Group Limited announced that they will report fiscal year 2024 results at 12:30 PM, China Standard Time on Jan 24, 2025
Valuation Update With 7 Day Price Move • Oct 01Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €1.19, the stock trades at a trailing P/E ratio of 7.1x. Average trailing P/E is 13x in the Real Estate industry in Germany. Total loss to shareholders of 26% over the past three years.
Reported Earnings • Sep 18First half 2024 earnings released: EPS: HK$0.65 (vs HK$1.24 in 1H 2023)First half 2024 results: EPS: HK$0.65 (down from HK$1.24 in 1H 2023). Revenue: HK$6.51b (up 16% from 1H 2023). Net income: HK$888.0m (down 47% from 1H 2023). Profit margin: 14% (down from 30% in 1H 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
Upcoming Dividend • Aug 07Upcoming dividend of HK$0.21 per shareEligible shareholders must have bought the stock before 14 August 2024. Payment date: 25 September 2024. Payout ratio is a comfortable 58% and this is well supported by cash flows. Trailing yield: 10%. Within top quartile of German dividend payers (4.9%). Higher than average of industry peers (2.9%).
Reported Earnings • Aug 01First half 2024 earnings released: EPS: HK$0.65 (vs HK$1.24 in 1H 2023)First half 2024 results: EPS: HK$0.65 (down from HK$1.24 in 1H 2023). Revenue: HK$6.51b (up 16% from 1H 2023). Net income: HK$888.0m (down 47% from 1H 2023). Profit margin: 14% (down from 30% in 1H 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
New Risk • Jul 31New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 17% Last year net profit margin: 27% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Profit margins are more than 30% lower than last year (17% net profit margin).
New Risk • Jul 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 18% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (6.7% average weekly change).
공고 • Jul 04Hang Lung Group Limited to Report First Half, 2024 Results on Jul 30, 2024Hang Lung Group Limited announced that they will report first half, 2024 results on Jul 30, 2024
공고 • Jun 21Hang Lung Group Limited Announces Audit Committee Changes, Effective July 1, 2024The board of Hang Lung Group Limited announced changes to the composition of the Audit Committee of the Company with effect from July 1, 2024. Professor Lap-Chee TSUI, an independent non-executive director of the Company, will cease to be a member of the Audit Committee; and Ms. May Siew Boi TAN, an independent non-executive director of the Company, will be appointed as a member of the Audit Committee. Professor TSUI will remain as an independent non-executive director of the Company.
Reported Earnings • Mar 31Full year 2023 earnings released: EPS: HK$2.06 (vs HK$2.00 in FY 2022)Full year 2023 results: EPS: HK$2.06 (up from HK$2.00 in FY 2022). Revenue: HK$11.0b (flat on FY 2022). Net income: HK$2.81b (up 3.4% from FY 2022). Profit margin: 26% (in line with FY 2022). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
Recent Insider Transactions • Feb 09Executive Vice Chair of the Board recently bought €230k worth of stockOn the 2nd of February, Wenbwo Chan bought around 200k shares on-market at roughly €1.15 per share. This transaction amounted to 67% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Wenbwo has been a buyer over the last 12 months, purchasing a net total of €569k worth in shares.
Declared Dividend • Feb 01Final dividend of HK$0.65 announcedShareholders will receive a dividend of HK$0.65. Ex-date: 8th May 2024 Payment date: 14th June 2024 Dividend yield will be 62%, which is higher than the industry average of 3.1%. Sustainability & Growth Dividend is well covered by both earnings (42% earnings payout ratio) and cash flows (25% cash payout ratio). The dividend has increased over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. The company's earnings per share (EPS) would need to decline by 54% to shift the payout ratio to a potentially unsustainable range, which is more than the 12% EPS decline seen over the last 5 years.
공고 • Jan 31Hang Lung Properties Limited and Hang Lung Group Limited Announce Retirement of Mr. Ronnie Chichung Chan as the Chair, an Executive Director, and the Chair of Executive Committees, with Effect from April 26, 2024The Boards of Directors of Hang Lung Group Limited (HLG) and Hang Lung Properties Limited (HLP, together with HLG, referred to as the Group) jointly announced that Mr. Ronnie Chichung CHAN (Mr. Ronnie Chan) will retire from his positions as the Chair, an Executive Director, and the Chair of Executive Committees of the Group with effect from the conclusion of the annual general meeting of each of HLG and HLP to be held on April 26, 2024 (the "2024 AGM"). Mr. Ronnie Chan will not take up a Non-Executive Director role in the Boards after his retirement. Mr. Ronnie Chan joined the Group in 1972 and has led the Group as the Chair since 1991. Mr. Ronnie Chan's vision and leadership established a strong foundation for the Group's sustainable growth. The Boards would like to express their deep gratitude to Mr. Ronnie Chan for his tremendous contributions to the Group. In recognition of his tremendous contributions, the Boards will bestow upon Mr. Ronnie Chan the title of the "Honorary Chair" of the Group after his retirement.
Reported Earnings • Jan 31Full year 2023 earnings released: EPS: HK$2.06 (vs HK$2.00 in FY 2022)Full year 2023 results: EPS: HK$2.06 (up from HK$2.00 in FY 2022). Revenue: HK$11.0b (flat on FY 2022). Net income: HK$2.81b (up 3.4% from FY 2022). Profit margin: 26% (up from 25% in FY 2022). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.
공고 • Jan 30+ 1 more updateHang Lung Group Limited Appoints Ms. May Siew Boi Tan as an Independent Non-Executive Director, with Effect from March 20, 2024The Board of Directors of Hang Lung Group Limited announced that Ms. May Siew Boi TAN ("Ms. Tan") will be appointed as an Independent Non-Executive Director ("INED") of the Company with effect from March 20, 2024. Ms. Tan, aged 68, graduated from The University of Sheffield, and is a Fellow of The Institute of Chartered Accountants in England and Wales and a Fellow of The Hong Kong Institute of Certified Public Accountants. Ms. Tan is an INED, the Chair of the Audit & Risk Committee, and a Member of the Nomination Committee, the Finance & General Committee, the Sustainability Committee, and the Human Resources & Remuneration Committee, of CLP Holdings Limited. She is also an INED, a Member of the Audit Committee and the Corporate Governance and Nominating Committee, of Manulife Financial Corporation. She holds the positions as a Board Member of Anticimex New TopHolding AB; and a Director of MSIG Insurance (Hong Kong) Limited. Ms. Tan was an INED of JPMorgan China Growth & Income plc from August 2021 to January 2024; an INED of Link Asset Management Ltd. (as manager of Link Real Estate Investment Trust) from February 2013 to January 2022; and an INED of HSBC Insurance (Asia) Limited and HSBC Life (International) Limited from 2018 to 2021. She was an Executive Director and the Chief Executive Officer of Standard Chartered Bank (Hong Kong) Limited* from July 2014 to February 2017. Ms. Tan joined Standard Chartered Bank in 2009 as Global Head, Equity Corporate Finance. She was previously the Chief Executive Officer of Cazenove Asia Limited, and was a partner of Cazenove and Co. Cazenove Asia Limited (now known as Standard Chartered Securities (Hong Kong) Limited) became part of Standard Chartered Hong Kong in January 2009. Service from 2015 to 2020. In 2016, Ms. Tan was the Chairman of the Hong Kong Association of Banks, the Ex-officio Member of The Hong Kong Trade Development Council and a Member of the Currency Board Sub-Committee of the Exchange Fund Advisory Committee of Hong Kong Monetary Authority. She was a Member of the Listing Committee of The Stock Exchange of Hong Kong Limited from 2012 to 2015 and a Member of the Takeovers and Mergers Panel and the Takeovers Appeal Committee of the Securities and Futures Commission from 2001 to 2013. Ms. Tan was also a Council Member from 2008 to 2017 and the Vice Chairman from 2012 to 2017 of Oxfam Hong Kong.
공고 • Jan 06Hang Lung Group Limited to Report Fiscal Year 2023 Results on Jan 30, 2024Hang Lung Group Limited announced that they will report fiscal year 2023 results on Jan 30, 2024
Upcoming Dividend • Sep 05Upcoming dividend of HK$0.21 per share at 7.8% yieldEligible shareholders must have bought the stock before 12 September 2023. Payment date: 29 September 2023. Payout ratio is a comfortable 40% and this is well supported by cash flows. Trailing yield: 7.8%. Within top quartile of German dividend payers (4.8%). Higher than average of industry peers (3.6%).
Reported Earnings • Aug 02First half 2023 earnings released: EPS: HK$1.24 (vs HK$1.06 in 1H 2022)First half 2023 results: EPS: HK$1.24 (up from HK$1.06 in 1H 2022). Revenue: HK$5.60b (down 2.2% from 1H 2022). Net income: HK$1.68b (up 17% from 1H 2022). Profit margin: 30% (up from 25% in 1H 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
공고 • Aug 01Hang Lung Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2023, Payable on 29 September 2023Hang Lung Group Limited announced Interim Dividend for the six months ended 30 June 2023 of HKD 0.21 per share. Ex-dividend date 12 September 2023. Record date 15 September 2023. Payment date 29 September 2023.
공고 • Jul 04Hang Lung Group Limited to Report First Half, 2023 Results on Jul 31, 2023Hang Lung Group Limited announced that they will report first half, 2023 results on Jul 31, 2023
Upcoming Dividend • Apr 26Upcoming dividend of HK$0.65 per share at 6.3% yieldEligible shareholders must have bought the stock before 03 May 2023. Payment date: 19 May 2023. Payout ratio is a comfortable 43% and this is well supported by cash flows. Trailing yield: 6.3%. Within top quartile of German dividend payers (4.6%). Higher than average of industry peers (3.9%).
Reported Earnings • Apr 06Full year 2022 earnings released: EPS: HK$2.00 (vs HK$1.90 in FY 2021)Full year 2022 results: EPS: HK$2.00 (up from HK$1.90 in FY 2021). Revenue: HK$11.1b (up 1.7% from FY 2021). Net income: HK$2.72b (up 5.0% from FY 2021). Profit margin: 25% (in line with FY 2021). Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 9% per year.
Buying Opportunity • Feb 16Now 20% undervaluedOver the last 90 days, the stock is up 13%. The fair value is estimated to be €2.14, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.7% over the last 3 years. Earnings per share has declined by 9.6%.
Reported Earnings • Feb 02Full year 2022 earnings released: EPS: HK$2.00 (vs HK$1.90 in FY 2021)Full year 2022 results: EPS: HK$2.00 (up from HK$1.90 in FY 2021). Revenue: HK$10.9b (flat on FY 2021). Net income: HK$2.72b (up 5.0% from FY 2021). Profit margin: 25% (up from 24% in FY 2021). Over the last 3 years on average, earnings per share has fallen by 10% per year and the company’s share price has also fallen by 10% per year.
공고 • Feb 01Hang Lung Group Limited Proposes Final Dividend for the Year Ended 31 December 2022, Payable on 19 May 2023Hang Lung Group Limited proposed Final Dividend of HKD 0.65 per share for the year ended 31 December 2022. Ex-dividend date is 03 May 2023. Record date is 05 May 2023. Payment date is 19 May 2023. Date of shareholders' approval is 28 April 2023.
Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 5 experienced directors. 5 highly experienced directors. 4 independent directors (7 non-independent directors). Independent Non-Executive Director Pak Wai Liu was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Sep 18First half 2022 earnings released: EPS: HK$1.06 (vs HK$1.11 in 1H 2021)First half 2022 results: EPS: HK$1.06 (down from HK$1.11 in 1H 2021). Revenue: HK$5.72b (up 9.1% from 1H 2021). Net income: HK$1.44b (down 4.6% from 1H 2021). Profit margin: 25% (down from 29% in 1H 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
Upcoming Dividend • Sep 02Upcoming dividend of HK$0.21 per shareEligible shareholders must have bought the stock before 09 September 2022. Payment date: 29 September 2022. Payout ratio is a comfortable 46% and this is well supported by cash flows. Trailing yield: 6.4%. Within top quartile of German dividend payers (4.8%). Higher than average of industry peers (5.2%).
Recent Insider Transactions • Aug 16CEO & Executive Director recently bought €83k worth of stockOn the 10th of August, Wai Pak Lo bought around 50k shares on-market at roughly €1.67 per share. This was the largest purchase by an insider in the last 3 months. Wai Pak has been a buyer over the last 12 months, purchasing a net total of €492k worth in shares.
Reported Earnings • Jul 29First half 2022 earnings releasedFirst half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (down HK$1.51b from profit in 1H 2021). Profit margin: (down from 29% in 1H 2021). The decrease in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
공고 • Jul 29Hang Lung Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2022, Payable on 29 September 2022Hang Lung Group Limited announced Interim Dividend for the six months ended 30 June 2022. Dividend declared is HKD 0.21 per share. Ex-dividend date is 09 September 2022. Record date is 15 September 2022. Payment date is 29 September 2022.
공고 • Jul 05Hang Lung Group Limited to Report First Half, 2022 Results on Jul 28, 2022Hang Lung Group Limited announced that they will report first half, 2022 results on Jul 28, 2022
공고 • Apr 28Hang Lung Group Limited Approves Final DividendHang Lung Group Limited approved the final dividend of 65 Hong Kong cents per share in annual general meeting held on April 27, 2022.
Board Change • Apr 27Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 7 experienced directors. 3 highly experienced directors. 4 independent directors (7 non-independent directors). Independent Non-Executive Director Pak Wai Liu was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Upcoming Dividend • Apr 22Upcoming dividend of HK$0.65 per shareEligible shareholders must have bought the stock before 29 April 2022. Payment date: 19 May 2022. Payout ratio is a comfortable 45% and this is well supported by cash flows. Trailing yield: 5.2%. Within top quartile of German dividend payers (3.8%). Higher than average of industry peers (3.7%).
Reported Earnings • Jan 28Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: HK$1.90 (up from HK$1.13 loss in FY 2020). Revenue: HK$10.9b (up 18% from FY 2020). Net income: HK$2.59b (up HK$4.13b from FY 2020). Profit margin: 24% (up from net loss in FY 2020). The move to profitability was primarily driven by lower expenses. Revenue missed analyst estimates by 11%. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
공고 • Jan 28+ 1 more updateHang Lung Group Limited Proposes Final Dividend for the Year Ended December 31, 2021, Payable on May 19, 2022Hang Lung Group Limited proposed final dividend of HKD 0.65 per share for the year ended December 31, 2021. Ex-dividend date is April 29, 2022. Record date is May 04, 2022. Payment date is May 19, 2022.
Reported Earnings • Sep 18First half 2021 earnings released: EPS HK$1.11 (vs HK$1.17 loss in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: HK$5.24b (up 22% from 1H 2020). Net income: HK$1.51b (up HK$3.10b from 1H 2020). Profit margin: 29% (up from net loss in 1H 2020). Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.
Recent Insider Transactions • Sep 12CEO & Executive Director recently bought €307k worth of stockOn the 8th of September, Wai Pak Lo bought around 150k shares on-market at roughly €2.05 per share. This was the largest purchase by an insider in the last 3 months. This was Wai Pak's only on-market trade for the last 12 months.
Upcoming Dividend • Sep 03Upcoming dividend of HK$0.21 per shareEligible shareholders must have bought the stock before 10 September 2021. Payment date: 29 September 2021. Trailing yield: 4.4%. Within top quartile of German dividend payers (3.1%). Higher than average of industry peers (2.9%).
Recent Insider Transactions • Sep 02CFO & Executive Director recently bought €61k worth of stockOn the 26th of August, Hau Cheong Ho bought around 29k shares on-market at roughly €2.11 per share. This was the largest purchase by an insider in the last 3 months. Hau Cheong has been a buyer over the last 12 months, purchasing a net total of €107k worth in shares.
Reported Earnings • Aug 02First half 2021 earnings released: EPS HK$1.11 (vs HK$1.17 loss in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: HK$5.24b (up 22% from 1H 2020). Net income: HK$1.51b (up HK$3.10b from 1H 2020). Profit margin: 29% (up from net loss in 1H 2020). Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.
Executive Departure • May 07Director of General Counsel has left the companyOn the 1st of May, Ka Man Yan's tenure as Director of General Counsel ended after 3.8 years in the role. We don't have any record of a personal shareholding under Ka Man's name. Ka Man is the only executive to leave the company over the last 12 months.
공고 • May 01Hang Lung Group Limited Declares Final Dividend for the Year 2020Hang Lung Group Limited declares a final dividend of 63 Hong Kong cents per share, at its AGM to be held on April 29, 2020.
Upcoming Dividend • Apr 27Upcoming dividend of HK$0.63 per shareEligible shareholders must have bought the stock before 04 May 2021. Payment date: 20 May 2021. Trailing yield: 4.0%. Within top quartile of German dividend payers (3.2%). Higher than average of industry peers (3.1%).
Reported Earnings • Mar 26Full year 2020 earnings released: HK$1.13 loss per share (vs HK$5.01 profit in FY 2019)The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2020 results: Revenue: HK$9.24b (down 4.0% from FY 2019). Net loss: HK$1.54b (down 123% from profit in FY 2019). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.
Reported Earnings • Jan 29Full year 2020 earnings released: HK$1.13 loss per share (vs HK$5.01 profit in FY 2019)The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2020 results: Revenue: HK$9.53b (down 1.0% from FY 2019). Net loss: HK$1.54b (down 123% from profit in FY 2019). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.
공고 • Jan 28Hang Lung Group Limited, Annual General Meeting, Apr 30, 2021Hang Lung Group Limited, Annual General Meeting, Apr 30, 2021.
Is New 90 Day High Low • Jan 27New 90-day high: €2.26The company is up 19% from its price of €1.90 on 29 October 2020. The German market is up 21% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Real Estate industry, which is up 9.0% over the same period.
공고 • Jan 07Hang Lung Group Limited to Report Fiscal Year 2020 Results on Jan 28, 2021Hang Lung Group Limited announced that they will report fiscal year 2020 results on Jan 28, 2021
공고 • Nov 21Hang Lung Group Limited Enters into the Lease Agreement as Tenant with Hang Lung as the LandlordThe Board announced that Top Glorification, an indirect wholly-owned subsidiary of the Company, entered into the Lease Agreement as tenant with Hang Lung as the landlord in respect of the Premises on 20 November 2020, for a term of three years commencing on 1 November 2020 and expiring on 31 October 2023 (both days inclusive) for the operation of its restaurant "Duddell's". Pursuant to HKFRS 16, the entering into of the Agreement will require the Group to recognise the fixed portion of the lease payment for the Premises as the right-of-use assets with a cost of approximately HKD 19.0 million at initial recognition and a corresponding lease liability which represented the present value of the future lease payments. Thus, the entering into the Lease Agreement and the transactions contemplated thereunder will be regarded as deemed acquisition of asset by the Group. REASONS FOR AND BENEFITS OF ENTERING INTO THE LEASE AGREEMENT: The Group is principally engaged in operating restaurants and providing membership services for the Group's restaurants in Hong Kong. The Premises have been leased to Top Glorification since May 2013 to operate the Group 's restaurant "Duddell's". The existing lease agreement for the Premises will expire on 31 October 2020. The Lease Agreement allows "Duddell's" to operate in the same location at Premises after the expiry of the existing lease agreement on 31 October 2020, which will facilitate the long-term success of the restaurant. Based on the above, the Directors are of the view that the terms and conditions of the Lease Agreement are fair and reasonable and in the interests of the Company and its shareholders as a whole.
Is New 90 Day High Low • Oct 31New 90-day low: €1.88The company is down 7.0% from its price of €2.02 on 31 July 2020. The German market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Real Estate industry, which is down 2.0% over the same period.
Is New 90 Day High Low • Sep 29New 90-day low: €1.94The company is down 6.0% from its price of €2.06 on 01 July 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Real Estate industry, which is up 4.0% over the same period.
